APC 100

Drug Profile

APC 100

Alternative Names: APC-100; CPC-100

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Adamis Pharmaceuticals Corporation
  • Class Anti-inflammatories; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Antioxidants; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 19 Jan 2015 APC 100 is still in a phase I/IIa trial for Prostate cancer in USA
  • 21 Aug 2013 APC 100 is still in a phase I/IIa trial for Prostate cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top